Analyst Price Targets — KLRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 11:40 am | — | Leerink Partners | $36.00 | $22.93 | TheFly | Kailera Therapeutics initiated with an Outperform at Leerink |
| May 12, 2026 9:00 am | — | Jefferies | $48.00 | $22.93 | TheFly | Kailera Therapeutics initiated with a Buy at Jefferies |
Latest News for KLRA
Don't wait until clinical milestones send their share prices soaring.
Kailera is building a multi-modal obesity franchise with exclusive global rights to Hengrui Pharma's obesity portfolio, leveraging late-stage assets and ongoing data. KLRA's robust cash position—over $1.3 billion post-IPO—funds operations through mid-2028, supporting multiple pivotal trial readouts before further capital is needed. Pipeline catalysts include global Phase 3 trials for ribupatide and promising Phase…
Kailera Therapeutics Inc. (NASDAQ:KLRA) stock fell about 9% on Tuesday after the company reported positive topline results from two Phase 3 trials of its oral GLP-1 drug candidate HRS-7535/KAI-7535 in China.
Kailera Therapeutics said on Tuesday its GLP-1 drug for patients with diabetes and obesity met the main goal of two-late stage trials.
Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Ka
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KLRA.
U.S. House Trading
No House trades found for KLRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.